Alethia Young - 02 Oct 2025 Form 4 Insider Report for BICYCLE THERAPEUTICS PLC (BCYC)

Role
Chief Financial Officer
Signature
/s/ Travis Thompson, Attorney-in-Fact
Issuer symbol
BCYC
Transactions as of
02 Oct 2025
Transactions value $
-$4,103
Form type
4
Filing time
06 Oct 2025, 16:45:09 UTC
Previous filing
07 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Young Alethia Chief Financial Officer C/O BICYCLE THERAPEUTICS PLC, BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, UNITED KINGDOM /s/ Travis Thompson, Attorney-in-Fact 06 Oct 2025 0001918147

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCYC Ordinary Shares Sale -$1.82K -217 -0.48% $8.40 45K 02 Oct 2025 Direct F1, F2
transaction BCYC Ordinary Shares Sale -$2.28K -265 -0.59% $8.61 44.7K 02 Oct 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.37 to $8.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on April 3, 2025.